Lymphocyte function in myasthenia gravis

S. KAWANAMI, A. KANAIDE, Y. ITOYAMA, AND Y. KUROIWA

From the Department of Neurology, Neurological Institute, and Department of Dermatology, Faculty of Medicine, Kyushu University, Fukuoka, Japan

SUMMARY Mitogen-induced blastoid transformation of peripheral blood lymphocytes from patients with myasthenia gravis was studied using a microplate culture technique and evaluated with ³H-thymidine incorporation. It was found that both phytohaemagglutinin and pokeweed mitogen responses decreased significantly in patients with myasthenia gravis. In myasthenic crisis, indices of stimulation by phytohaemagglutination became very low. The autologous plasma neither inhibited nor facilitated mitogenic responses of lymphocytes. The decreased mitogen responsiveness of lymphocytes suggests that part of the T lymphocyte function is subnormal in myasthenia.

An autoimmune pathogenesis of myasthenia gravis has frequently been postulated on the basis of clinical (Simpson, 1960) and laboratory investigations (Nastuk et al., 1960; Strauss et al., 1960; Almon et al., 1974; Lindstrom et al., 1976a,b). Since there are abnormalities in the myasthenic thymus, either thymic hyperplasia or thymoma (Castleman, 1966), and the thymus is known to be a central organ of the immune system (Miller, 1961, Komuro and Boyse, 1973), lymphocytes from patients with myasthenia gravis may function abnormally, causing the autoimmune processes.

The number of peripheral blood lymphocytes decreases during remission after thymectomy (Joske et al., 1958). There were no significant differences in peripheral blood lymphocyte subpopulations of myasthenia gravis patients and control subjects (Abdou et al., 1974; Shirai et al., 1976). Delayed hypersensitivity induced by 1-chloro-2, 4-dinitrobenzene has been reported to be either reduced (Adner et al., 1966) or normal (Kornfeld et al., 1965) in patients with myasthenia gravis. Lymphocytes of myasthenic patients caused a more severe systemic graft-versus-host reaction than normal human lymphocytes (Namba et al., 1969).

Studies of lymphocyte function using in vitro culture techniques have reported normal mitogenic responsiveness to phytohaemagglutinin (PHA) in both thymectomised and non-thymectomised patients (Housley and Oppenheim, 1967) and to PHA and pokeweed mitogen (PWM) (Lisak and Zweiman, 1975).

As for cellular immunity in myasthenia gravis, thymocytes and peripheral blood lymphocytes have been reported sensitised to muscle antigens (Alpert et al., 1972), acetylcholine receptor protein (Abramsky et al., 1975), or thymus tissue antigens (Goust et al., 1974; Kawanami et al., 1976).

In this study we examined lymphocyte functions by measuring mitogen responsiveness to PHA for T cells (Clot et al., 1975) and PWM in a lower concentration for B cells (Mellstedt, 1975) with respect to change in myasthenic crisis, change after thymectomy, and the effect of serum factor.

Methods

Defibrinated venous blood was obtained with a heparinised syringe. An equal volume of 0.9% sodium chloride solution was mixed with the blood. The lymphocyte suspension was cleared from the red cells and polymorphous leucocytes by centrifugation through a Ficoll-Conray gradient. The lymphocyte layer remaining at the interface was removed into an equal volume of Eagle's MEM, washed three times, and finally resuspended one million lymphocytes per ml in RPMI 1640 containing penicillin (500 units/ml), streptomycin (50 μg/ml) and 20% heat-inactivated fetal calf serum (Gibco).

 Cultures were done using microplates (Falcon plastics, No. 3040) (Knoke et al., 1974). Each cul-

Address for reprint requests: Dr Sachiko Kawanami, Division of Neurology, Fukuoka University Hospital, 34 Nanakuma, Nishi-ku, Fukuoka City, Japan 814.

Accepted 1 February 1979
Lymphocyte function in myasthenia gravis

Intrathymic lymphocytes were very gently pared by clumps with six patients, aged 14-20 years. All patients, five (14 thymomas were added to a plate and returned to a T cell marker. The presence of receptor for complement on lymphocytes was used to search for B cells. For the anti-SRBC sera, either whole anti-SRBC rabbit serum or its IgM fraction was used. These were designated erythrocyte-haemolysin-complements rosette forming cells, EA(H)C-RFC, and erythrocyte-IgM-complements rosette forming cells, EA(M)C-RFC (Itoyama et al., to be published).

The lymphocytes were obtained by Conray-Ficoll gradient centrifugation at 400 g for 30 minutes. After washing, the cells were resuspended to one million/ml of RPMI 1640 containing 20% fetal calf serum. The subpopulations of lymphocytes were detected by the rosette forming method described by Yata et al. (1973), with slight modifications. In our study, the spontaneous rosette forming capacity of lymphocytes with sheep red blood cells (SRBC) was used for a T cell marker. The presence of receptor for complement on lymphocytes was used to search for B cells. For the anti-SRBC sera, either whole anti-SRBC rabbit serum or its IgM fraction was used. These were designated erythrocyte-haemolysin-complements rosette forming cells, EA(H)C-RFC, and erythrocyte-IgM-complements rosette forming cells, EA(M)C-RFC (Itoyama et al., to be published).

Results

PHA RESPONSE

The mitogenic responses of lymphocytes from patients with myasthenia gravis and normal control subjects are shown in Fig. 1. The mean PHA responses of 13 normal controls, 18 non-thymectomised patients, and 13 thymectomised patients were 123.9±16.3, (mean±SE), 59.7±7.7, and 62.5±12.0, respectively, (Table 1). The mean stimulation indices of both the thymectomised and non-thymectomised groups of patients with myasthenia gravis were lower than those of normal control subjects (P<0.01).

We studied three patients in myasthenic crisis (Table 2). The lymphocytes were obtained before steroid administration. The PHA-SI decreased remarkably during myasthenic crisis and returned to its pre-crisis level during recovery from the crisis. The stimulation indices for PHA were lower in intrathymic lymphocytes from myasthenic thymus or thymoma than in peripheral blood lymphocytes. The study on the subpopulations of the lymphocytes revealed that the percentage of erythrocyte (SRBC)-rosette forming cells was not lower than in peripheral blood lymphocytes (Table 3).

PWM RESPONSE

The results of lymphocyte transformation by PWM are shown in Fig. 2. The mean value of the PWM-SI of lymphocytes from 10 normal control subjects, 17 non-thymectomised, and 13 thymectomised myasthenia gravis patients were 43.3±5.1 (mean±SE), 24.1±3.9, and 22.5±3.6, respectively. Whether or not the thymus had been
removal, the means of the PWM stimulation indices for the group of patients with myasthenia gravis were significantly lower than those of the control subjects (P<0.01).

**EFFECT OF PLASMA**

Study of the effect of plasma on lymphocyte transformation revealed that there was no definite inhibition or facilitation of mitogenic responses in both PHA and PWM stimulation (Fig. 3).

**Discussion**

The in vitro mitogen responsiveness of lymphocytes from patients with myasthenia gravis has been reported as normal. Housley and Oppenheim (1967) compared the capacity of lymphocytes from thymectomised and non-thymectomised myasthenics to react in vitro to PHA and found no differences between them. They used Eagle's MEM with autologous plasma as medium and cultured for five days. Abdou et al. (1974) reported that the peripheral blood lymphocytes of patients with myasthenia gravis and control subjects proliferated without significant differences in response to PHA in cultures carried out for three to five days in medium 199 with autologous plasma or fetal calf serum. Lisak and Zweiman (1975) found no impairment of peripheral blood lymphocyte responses to mitogens, PHA and PWM, in myasthenia gravis. They cultured for five days and the degree of proliferative response was assayed by the incorporation of ³H-thymidine added 18 hours before termination of the culture. Hammarström et al. (1975) found no significant differences in the

---

**Table 2** Lymphocyte transformation during and after myasthenic crisis

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Time of study</th>
<th>PHA-SI</th>
</tr>
</thead>
<tbody>
<tr>
<td>NB</td>
<td>22</td>
<td>F</td>
<td>In crisis</td>
<td>2.63</td>
</tr>
<tr>
<td>FO</td>
<td>26</td>
<td>M</td>
<td>In crisis</td>
<td>9.03</td>
</tr>
<tr>
<td>HD</td>
<td>22</td>
<td>F</td>
<td>In crisis</td>
<td>5.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>25 days after</td>
<td>122.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 days after</td>
<td>70.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15 days after</td>
<td>151.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>11 months after</td>
<td>83.3</td>
</tr>
</tbody>
</table>

PHA-SI=stimulation indices with PHA; crisis=at the stage of myasthenic crisis.

**Table 3** PHA responses and subpopulations of lymphocytes obtained from myasthenic thymus or thymoma

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Origin</th>
<th>PHA-SI</th>
<th>E-RFC</th>
<th>EA(H)C-RFC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NY</td>
<td>18</td>
<td>F</td>
<td>Thymoma</td>
<td>12.0*</td>
<td>89.7(%)</td>
<td>12.3(%)</td>
</tr>
<tr>
<td>NI</td>
<td>52</td>
<td>F</td>
<td>Thymus</td>
<td>8.0*</td>
<td>90.3</td>
<td>10.0</td>
</tr>
<tr>
<td>MK</td>
<td>25</td>
<td>M</td>
<td>Thymus</td>
<td>25.0*</td>
<td>95.7</td>
<td>4.0</td>
</tr>
</tbody>
</table>

PHA-SI=stimulation index with PHA. The concentration of PHA was described as the ratio of dilution from the 5ml vial of PHA (Difco), *=1:40, †=1:100. E-RFC, erythrocyte rosette forming cells; EA(H)C-RFC, erythrocyte haemolysin complements rosette forming cells.

---

**Fig. 1** Lymphocyte transformation with phytohaemagglutinin (PHA) diluted to 1:100. SI (stimulation index): the ratio of uptake of "H-thymidine by the stimulated culture to the uptake of a simultaneously incubated unstimulated culture was calculated. Stimulation index (SI)=mean cpm of triplicate culture with mitogen/mean cpm of triplicate culture without mitogen. MG=myasthenia gravis; thymex=thymectomised. Dotted lines indicate mean values.

**Table 1** In vitro lymphocyte transformation by mitogens

<table>
<thead>
<tr>
<th></th>
<th>PHA-SI</th>
<th>PWM-SI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>n=13 123.9±16.3</td>
<td>n=10 43.5±5.1</td>
</tr>
<tr>
<td>MG</td>
<td>n=18 59.7±7.7*</td>
<td>n=17 24.1±3.9*</td>
</tr>
<tr>
<td>MG–Thymex</td>
<td>n=13 62.5±12.0*</td>
<td>n=13 22.5±3.6*</td>
</tr>
</tbody>
</table>

*P<0.01, mean ± SE.

PHA-SI=stimulation indices with PHA; PWM-SI=stimulation indices with pokeweed mitogen; MG=myasthenia gravis; MG-Thymem-thymectomised patients with MG; n=numbers of patients or normal control subjects examined.
Lymphocyte function in myasthenia gravis

responsiveness of thoracic duct lymphocytes from patients with myasthenia gravis compared to normal peripheral blood lymphocytes. Although their cultures were performed using Eagle's MEM with 10% CO₂, the lymphocytes had been stored in liquid nitrogen with dimethylsulphoxide added to the medium until culture.

These reports differed from our study in the duration of cultures, culture media, concentration of mitogens, and the method of lymphocyte preparation. Autologous plasma was occasionally used in place of calf serum. It is well known that the mitogenic responses of lymphocytes reach their maximum level on the second to the third day, and the viability of lymphocytes decreases remarkably during longer culture periods (Knight et al., 1968). Autologous plasma modifies the lymphocyte responses to mitogens as shown in Fig. 3, and many humoral factors (Newberry et al., 1973; Han, 1974; Hsu, 1976; Mendelsohn et al., 1977) are known to have an effect on lymphocyte functions.

Results of the present study revealed that lymphocytes from patients with myasthenia gravis had a lower response to mitogens, both PHA and PWM. Only in two reports were similar mitogenic responses in lymphocytes from patients with myasthenia gravis described (Arimori et al., 1974; Simpson et al., 1976). This lower responsiveness may be due to the difference in lymphocyte subpopulation. Our study showed (Itoyama et al., to be published) that the percentage of E rosette forming cells both in thymomatous and non-thymomatous patients did not differ from normal controls. Only B cells detected by EA(H)C-RFC were significantly increased in myasthenia gravis. The EA(H)C-RFC are supposed to include B cells and T cells bearing Fc receptors. Increase of T cells bearing Fc receptors was also reported in Japanese myasthenics (Yata et al., 1977). Mitogen responsiveness of the T lymphocyte bearing Fc receptor has been noted as normal to PHA and concanavalin A (Stout and Herzenberg, 1975). However, Moretta et al. (1976) reported that the T lymphocyte bearing Fc receptor of IgG showed

Fig. 2 Lymphocyte transformation with pokeweed mitogen, 5 μg/ml in final concentration. SI = stimulation indices, MG = myasthenia gravis, thymex = thymectomised.

Fig. 3 Plasma effect on lymphocyte transformation. The mitogenic stimulation indices of lymphocytes from patients with myasthenia gravis and normal control subjects are illustrated. Circles indicate patients and squares show normal controls. Open circles or squares indicate stimulation indices of lymphocyte culture using fetal calf serum. Closed circles or squares indicate the PHA-SI of cultures in media including autoplasma instead of fetal calf serum.
a lower response to PHA. The low mitogen responsiveness of lymphocytes from myasthenic patients may be explained partly by the change of subpopulation of T lymphocytes, with increase of the T lymphocyte bearing Fc receptors. These lymphocytes can be helper or suppressor T cells and may cause production of autoantibodies or cellular sensitisation.

Depression of T lymphocyte function has been found in patients with malignancy and other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Decrease of T lymphocytes and the presence of natural thymocyte cytotoxic autoantibodies have been noted with exacerbation of systemic lupus erythematosus. Recently, loss of the suppressor function of T lymphocytes has been reported in patients with active systemic lupus erythematosus (Morimoto, 1978), although it remains to be determined whether these changes are primary or not.

To investigate the cause of the suppressed response to mitogens in lymphocytes from patients with myasthenia gravis, we examined the effect of autologous plasma. No definite inhibition of mitogenic response was found with either PHA or PWM. This means that humoral factors, such as those seen in liver diseases or carcinoma, cannot be a reason for the lower mitogenic response.

As far as we know, there has been no report on lymphocyte function during myasthenic crisis. In our study, the responsiveness to PHA became extremely low during myasthenic crisis. Humoral factors, including steroid hormones and cellular immunological events at crisis, may be the key to the problem.

There was no significant correlation between the level of immunoglobulin, IgG, IgM, IgA, and the mitogen responsiveness of lymphocytes from these myasthenic patients. The titre of antibody for acetylcholine receptor protein was not measured. Myasthenic serum has been reported to have increased antibodies to acetylcholine receptor protein and the antibodies are thought to be one of the causes of myasthenia gravis (Lindstrom et al., 1976a; Monnier and Fulpius, 1977). It is known that lymphocytes have cholinergic receptors on their surface membranes (Hadden et al., 1973; Strom et al., 1972). Secondly, one of the reasons for the lower mitogenic response in myasthenic lymphocytes may be a modification induced by an immunological reaction between acetylcholine receptor on the lymphocytes and the antibody to the acetylcholine receptor of the muscle membrane.

According to the thymopoietin theory (Goldstein and Schlesinger, 1975), myasthenic serum includes thymopoietin, which has the capacity to impair neuromuscular transmission in vivo and to induce expression of T cell antigens in vitro (Basch and Goldstein, 1975), that is TL antigen in mice. In mice, TL positive lymphocytes are present in the cortex of the thymus as premature thymocytes (Konda et al., 1973). In the human, intrathymic lymphocytes have a lower PHA response than peripheral blood lymphocytes (Table 3; Armstrong et al., 1973; Abdou et al., 1974). In mixed leucocyte reactions, thymic cells from patients with myasthenia gravis and thymic hyperplasia were reported capable of stimulating autologous peripheral blood lymphocytes (Abdou et al., 1974). In myasthenic crisis, the concentration of thymopoietin in serum is supposed to increase remarkably. It may cause changes in receptors on T lymphocytes and thus decrease PHA response in vitro to a point below normal. As a third possibility, it is conceivable that in human myasthenia gravis the receptors on T lymphocytes are modified by thymopoietin, resulting in reduced response to mitogens. More simply, in myasthenic crisis, intrathymic lymphocytes may be released from the thymus into peripheral blood, causing a reduced response to mitogens. Both anti-acetylcholine receptor antibodies and thymopoietin may cause the reduced response of lymphocytes to mitogens in myasthenia gravis.

We would like to thank Dr K. Konomi and his colleagues in the Department of Surgery, Faculty of Medicine, Kyushu University for their collaboration. This work was supported by grants from the Japanese Ministry of Welfare.

References


Lymphocyte function in myasthenia gravis


Lymphocyte function in myasthenia gravis.

S Kawanami, A Kanaide, Y Itoyama and Y Kuroiwa

_J Neurol Neurosurg Psychiatry_ 1979 42: 734-740
doi: 10.1136/jnnp.42.8.734

Updated information and services can be found at:
http://jnnp.bmj.com/content/42/8/734

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/